A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
Shanghai Henlius Biotech
University of Wisconsin, Madison
University of California, Irvine
University of Michigan Rogel Cancer Center
Universitaire Ziekenhuizen KU Leuven
Pfizer
Shanghai Zhongshan Hospital
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
M.D. Anderson Cancer Center
Biocon Limited
University of Pittsburgh
NYU Langone Health
Shanghai Zhongshan Hospital
Herlev Hospital
University of Zurich
Bristol-Myers Squibb
Rapa Therapeutics LLC
University Hospital Augsburg
Case Comprehensive Cancer Center
Alvotech Swiss AG
Duke University
Philogen S.p.A.
Philogen S.p.A.
Bristol-Myers Squibb
Jules Bordet Institute
University of Pittsburgh
M.D. Anderson Cancer Center
Kaiser Permanente
Dana-Farber Cancer Institute
OHSU Knight Cancer Institute
Qingdao Sino-Cell Biomedicine Co., Ltd.
West Virginia University
Indiana University
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Helsinki University Central Hospital
National University Hospital, Singapore
VA Office of Research and Development
Second Life Therapeutics
Onchilles Pharma Inc
UNICANCER
Universitaire Ziekenhuizen KU Leuven
McMaster University
Ohio State University Comprehensive Cancer Center
University Hospital, Lille
Alpha Tau Medical LTD.
AccSalus Biosciences, Inc.
Petrov, Andrey
Centre Hospitalier Universitaire de Nīmes
Eastern Cooperative Oncology Group
Assistance Publique - Hôpitaux de Paris